Bimekizumab efficacy and safety through two years in patients with moderate psoriasis: Analysis of pooled data from five phase 3/3b clinical trials

Main Article Content

Andrew Blauvelt
Linda Stein Gold
Melinda Gooderham
Bruce Strober
Andreas Pinter
Jose-Manuel Carrascosa
Paolo Gisondi
Jonathan Bleier
Cynthia Madden
Delphine Deherder
Natalie Nunez Gomez
Richard B Warren


bimekizumab, psoriasis, biologic, pooled data, efficacy, safety, phase 3, clinical trial




1. Reich K et al. Lancet 2021;397:487–98, NCT03370133

2. Gordon KB et al. Lancet 2021;397:475–86, NCT03410992

3. Warren RB et al. N Engl J Med 2021;385:130–41, NCT03412747

4. Reich K et al. N Engl J Med 2021;385:142–52, NCT03536884

5. BE BRIGHT:; 6Gordon KB et al. JAMA Dermatol 2022; published online ahead of print

Most read articles by the same author(s)

<< < 3 4 5 6 7 8 9 10 11 12 > >>